Abstract
Purpose
The DNA-demethylating agent decitabine has shown clinical response for the treatment of hematological malignancies and solid tumors, while the mechanisms underlying its antitumor capacity are not fully understood.
Methods
The sensitivities of cancer cells to different chemotherapeutic drugs, such as cisplatin, paclitaxel, and 5-FU, were detected. The tumor sphere formation assay was used to evaluate the effects of low-dose decitabine on cancer-initiating stem cells.
Results
We observed that the chemotherapy sensitivity of various cancer cells was enhanced following non-toxic low-dose decitabine treatment. Moreover, low-dose decitabine treatment suppressed the self-renewal of cancer-initiating cells and inhibited the expression of pluripotency markers. Strikingly, low-dose decitabine was able to augment chemosensitivity in cancer stem cells, likely by the upregulation of miRNA-497, which was reported to be downregulated and to have promoted cell apoptosis in multiple cancers.
Conclusions
These results indicated that the DNA-demethylating agent could target cancer stem cells and reverse their chemotherapeutic resistance by regulating the endogenous expression of microRNAs.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ajani JA, Song S, Hochster HS, Steinberg IB (2015) Cancer stem cells: the promise and the potential. Semin Oncol 42(Suppl 1):S3–17
Azad N, Zahnow CA, Rudin CM, Baylin SB (2013) The future of epigenetic therapy in solid tumours—lessons from the past. Nat Rev Clin Oncol 10:256–266
Chang L, Graham PH, Hao J, Ni J, Bucci J, Cozzi PJ, Kearsley JH, Li Y (2013) Acquisition of epithelial–mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance. Cell Death Dis 4:e875
Chen J, Fu X, Wan Y, Wang Z, Jiang D, Shi L (2014) miR-125b inhibitor enhance the chemosensitivity of glioblastoma stem cells to temozolomide by targeting Bak1. Tumour Biol 35:6293–6302
Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, Hein A, Rote NS, Cope LM, Snyder A et al (2015) Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell 162:974–986
Clevers H (2011) The cancer stem cell: premises, promises and challenges. Nat Med 17:313–319
Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance. Nat Rev Cancer 5:275–284
Easwaran H, Tsai HC, Baylin SB (2014) Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell 54:716–727
Esteller M (2007) Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 8:286–298
Fan H, Lu X, Wang X, Liu Y, Guo B, Zhang Y, Zhang W, Nie J, Feng K, Chen M et al (2014) Low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I/II report. J Immunol Res 2014:371087
Fu X, Zhang Y, Wang X, Chen M, Wang Y, Nie J, Meng Y, Han W (2015) Low dose decitabine combined with taxol and platinum chemotherapy to treat refractory/recurrent ovarian cancer: an open-label, single-arm, phase I/II study. Curr Protein Pept Sci 16:329–336
Haghpanah V, Fallah P, Tavakoli R, Naderi M, Samimi H, Soleimani M, Larijani B (2015) Antisense-miR-21 enhances differentiation/apoptosis and reduces cancer stemness state on anaplastic thyroid cancer. Tumour Biol. doi:10.1007/s13277-015-3923-z
Han X, Du F, Jiang L, Zhu Y, Chen Z, Liu Y, Hong T, Wang T, Mao Y, Wu X et al (2013) A2780 human ovarian cancer cells with acquired paclitaxel resistance display cancer stem cell properties. Oncol Lett 6:1295–1298
Huang S, Guo W, Tang Y, Ren D, Zou X, Peng X (2012) miR-143 and miR-145 inhibit stem cell characteristics of PC-3 prostate cancer cells. Oncol Rep 28:1831–1837
Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, Klimek V, Slack J, de Castro C, Ravandi F et al (2006) Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106:1794–1803
Li X, Mei Q, Nie J, Fu X, Han W (2015) Decitabine: a promising epi-immunotherapeutic agent in solid tumors. Expert Rev Clin Immunol 11:363–375
Liu L, Chen L, Xu Y, Li R, Du X (2010) microRNA-195 promotes apoptosis and suppresses tumorigenicity of human colorectal cancer cells. Biochem Biophys Res Commun 400:236–240
Liu L, Zheng W, Song Y, Du X, Tang Y, Nie J, Han W (2015a) miRNA-497 enhances the sensitivity of colorectal cancer cells to neoadjuvant chemotherapeutic drug. Curr Protein Pept Sci 16:310–315
Liu WH, Chen MT, Wang ML, Lee YY, Chiou GY, Chien CS, Huang PI, Chen YW, Huang MC, Chiou SH et al (2015b) Cisplatin-selected resistance is associated with increased motility and stem-like properties via activation of STAT3/Snail axis in atypical teratoid/rhabdoid tumor cells. Oncotarget 6:1750–1768
Luo Q, Li X, Gao Y, Long Y, Chen L, Huang Y, Fang L (2013) MiRNA-497 regulates cell growth and invasion by targeting cyclin E1 in breast cancer. Cancer Cell Int 13:95
Mitra A, Mishra L, Li S (2015) EMT, CTCs and CSCs in tumor relapse and drug-resistance. Oncotarget 6:10697–10711
Nie J, Liu L, Zheng W, Chen L, Wu X, Xu Y, Du X, Han W (2012) microRNA-365, down-regulated in colon cancer, inhibits cell cycle progression and promotes apoptosis of colon cancer cells by probably targeting Cyclin D1 and Bcl-2. Carcinogenesis 33:220–225
Nie J, Liu L, Li X, Han W (2014) Decitabine, a new star in epigenetic therapy: the clinical application and biological mechanism in solid tumors. Cancer Lett 354:12–20
Park EY, Chang E, Lee EJ, Lee HW, Kang HG, Chun KH, Woo YM, Kong HK, Ko JY, Suzuki H et al (2014) Targeting of miR34a–NOTCH1 axis reduced breast cancer stemness and chemoresistance. Cancer Res 74:7573–7582
Roulois D, Loo Yau H, Singhania R, Wang Y, Danesh A, Shen SY, Han H, Liang G, Jones PA, Pugh TJ et al (2015) DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell 162:961–973
Sun FF, Hu YH, Xiong LP, Tu XY, Zhao JH, Chen SS, Song J, Ye XQ (2015) Enhanced expression of stem cell markers and drug resistance in sphere-forming non-small cell lung cancer cells. Int J Clin Exp Pathol 8:6287–6300
Troppan K, Wenzl K, Pichler M, Pursche B, Schwarzenbacher D, Feichtinger J, Thallinger GG, Beham-Schmid C, Neumeister P, Deutsch A (2015) miR-199a and miR-497 are associated with better overall survival due to increased chemosensitivity in diffuse large B-cell lymphoma patients. Int J Mol Sci 16:18077–18095
Tsai HC, Li H, Van Neste L, Cai Y, Robert C, Rassool FV, Shin JJ, Harbom KM, Beaty R, Pappou E et al (2012) Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 21:430–446
Tu Y, Liu L, Zhao D, Liu Y, Ma X, Fan Y, Wan L, Huang T, Cheng Z, Shen B (2015) Overexpression of miRNA-497 inhibits tumor angiogenesis by targeting VEGFR2. Sci Rep 5:13827
Yu W, Jin C, Lou X, Han X, Li L, He Y, Zhang H, Ma K, Zhu J, Cheng L et al (2011) Global analysis of DNA methylation by Methyl-Capture sequencing reveals epigenetic control of cisplatin resistance in ovarian cancer cell. PLoS One 6:e29450
Yu Y, Nangia-Makker P, Farhana L, Rajendra SG, Levi E, Majumdar AP (2015) miR-21 and miR-145 cooperation in regulation of colon cancer stem cells. Mol Cancer 14:98
Zeller C, Dai W, Steele NL, Siddiq A, Walley AJ, Wilhelm-Benartzi CS, Rizzo S, van der Zee A, Plumb JA, Brown R (2012) Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Oncogene 31:4567–4576
Zhao WY, Wang Y, An ZJ, Shi CG, Zhu GA, Wang B, Lu MY, Pan CK, Chen P (2013) Downregulation of miR-497 promotes tumor growth and angiogenesis by targeting HDGF in non-small cell lung cancer. Biochem Biophys Res Commun 435:466–471
Acknowledgments
This project is supported by grants from the Science and Technology Planning Project of Beijing City (Z151100003915076) and National Natural Science Foundation of China (Nos. 81302166, 81472838, 81230061, 31270820), Beijing Nova Programs (Z141107001814098, Z121107002512121), and PLA General Hospital Programs (2013FC-CXYY-1005).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
All of the experiments were approved by the ethics committee of General Hospital of PLA.
Conflict of interest
All of the authors declared no conflict of interest.
Ethical approval
This study did not involve any experiments with human participants or animals performed by any of the authors.
Additional information
Lin Liu and Lin Chen have contributed equally to this study.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Liu, L., Chen, L., Wu, X. et al. Low-dose DNA-demethylating agent enhances the chemosensitivity of cancer cells by targeting cancer stem cells via the upregulation of microRNA-497. J Cancer Res Clin Oncol 142, 1431–1439 (2016). https://doi.org/10.1007/s00432-016-2157-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-016-2157-9